Vir Biotechnology

Vir Biotechnology logo
🇺🇸United States
Ownership
Public
Established
2016-04-07
Employees
587
Market Cap
-
Website
http://www.vir.bio
Introduction

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting...

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2023-05-11
Last Posted Date
2024-10-10
Lead Sponsor
Vir Biotechnology, Inc.
Target Recruit Count
95
Registration Number
NCT05854381
Locations
🇿🇦

Setshaba Research Centre CRS, Soshanguve, Gauteng, South Africa

🇺🇸

Alabama CRS, Birmingham, Alabama, United States

🇺🇸

The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States

and more 7 locations

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-05-06
Last Posted Date
2024-05-03
Lead Sponsor
Vir Biotechnology, Inc.
Target Recruit Count
32
Registration Number
NCT05844228
Locations
🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

🇺🇸

Inland Empire Clinical Trials, Rialto, California, United States

🇺🇸

Floridian Clinical Research, Miami Lakes, Florida, United States

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2022-11-10
Last Posted Date
2024-02-20
Lead Sponsor
Vir Biotechnology, Inc.
Target Recruit Count
150
Registration Number
NCT05612581
Locations
🇬🇧

Investigative Site, Manchester, United Kingdom

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

First Posted Date
2022-10-05
Last Posted Date
2023-09-18
Lead Sponsor
Vir Biotechnology, Inc.
Target Recruit Count
2985
Registration Number
NCT05567783
Locations
🇺🇸

Investigative Site, Norfolk, Virginia, United States

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2022-08-02
Last Posted Date
2024-05-03
Lead Sponsor
Vir Biotechnology, Inc.
Target Recruit Count
144
Registration Number
NCT05484206
Locations
🇺🇸

Inland Empire Clinical Trials, Rialto, California, United States

🇺🇸

Orange County Research Center, Tustin, California, United States

🇺🇸

Floridian Clinical Research, Miami Lakes, Florida, United States

and more 2 locations

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-07-18
Last Posted Date
2024-08-09
Lead Sponsor
Vir Biotechnology, Inc.
Target Recruit Count
124
Registration Number
NCT05461170
Locations
🇬🇧

Investigative Site, Manchester, United Kingdom

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2022-03-15
Last Posted Date
2022-11-08
Lead Sponsor
Vir Biotechnology, Inc.
Target Recruit Count
504
Registration Number
NCT05280717
Locations
🇺🇸

Investigative Site, West Jordan, Utah, United States

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

Conditions
First Posted Date
2022-02-11
Last Posted Date
2022-11-10
Lead Sponsor
Vir Biotechnology, Inc.
Registration Number
NCT05235347
Locations
🇺🇸

Site, Seattle, Washington, United States

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-08-03
Last Posted Date
2024-06-07
Lead Sponsor
Vir Biotechnology, Inc.
Target Recruit Count
48
Registration Number
NCT04988152
Locations
🇺🇸

Investigative Site, Glendale, California, United States

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2021-06-04
Last Posted Date
2024-03-07
Lead Sponsor
Vir Biotechnology, Inc.
Target Recruit Count
1065
Registration Number
NCT04913675
Locations
🇺🇦

Investigative Site, Kyiv, Ukraine

🇺🇸

Investigative Sites, Pembroke Pines, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath